Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of WD-890 tablets in mild to moderate plaque psoriasis
CTR20263832Phase 2Active
- Sponsor
- Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WD-890 in plaque psoriasis, sponsored by Zhejiang Wenda Pharmaceutical Technology Co., Ltd.. Started Oct 2026; status: active.
02
Drugs
WD-890
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20263832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263832.